Preparation of purified lymphoma cells suitable for therapy

Cytotherapy

Volumn 6, Issue 3, 2004, Pages 235-243

  Lui, G ^a   Manches, O ^a   Chaperot, L ^a   Ducrot, T ^b   Molens, J P ^a   Sotto, J J ^c   Bensa, J C ^a   Plumas, Joël ^a  

^a ETABLISSEMENT FRANÇAIS DU SANG   (France)

^b Baxter SAS   (France)

^c Research Group on Lymphomas   (France)

Author keywords

Apoptosis; Clinical grade purification; Lymphoma; Necrosis; Rituximab

Indexed keywords

CD19 ANTIGEN; CD2 ANTIGEN; MONOCLONAL ANTIBODY; RITUXIMAB; TUMOR ANTIGEN;

ANTIGEN PRESENTING CELL; ANTIGEN PURIFICATION; APOPTOSIS; ARTICLE; ASEPSIS; B LYMPHOCYTE; CANCER IMMUNOTHERAPY; CELL DEATH; CELL LYSATE; CONTROLLED STUDY; HEATING; HUMAN; HUMAN CELL; IRRADIATION; LYMPH NODE BIOPSY; LYMPHOMA CELL; MAGNETIC SEPARATION; METHODOLOGY; NONHODGKIN LYMPHOMA; OPSONIZATION; PHAGOCYTOSIS; REPRODUCIBILITY; SPLEEN BIOPSY;

EID: 3042803918     PISSN: 14653249     EISSN: None     Source Type: Journal    
DOI: 10.1080/14653240410006059     Document Type: Article

References (28)

1. Gilboa E. The makings of a tumor rejection antigen. Immunity 1999;11:263-70.
2. Hsu FJ, Benike C, Fagnoni F et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996;2:52-8.
3. Hsu FJ, Caspar CB, Czerwinski D et al. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma - long-term results of a clinical trial. Blood 1997;89:3129-35.
4. Timmerman JM, Czerwinski DK, Davis TA et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 2002;99:1517-26.
5. Vonderheide RH, Hahn WC, Schultze JL, Nadler LM. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 1999;10:673-9.
6. Minev B, Hipp J, Firat H et al. Cytotoxic T cell immunity against telomerase reverse transcriptase in humans. Proc Natl Acad Sci USA 2000;97:4796-801.
7. Vonderheide RH, Schultze JL, Anderson KS et al. Equivalent induction of telomerase-specific cytotoxic T lymphocytes from tumor-bearing patients and healthy individuals. Cancer Res 2001;61:8366-70.
8. Scardino A, Gross DA, Alves P et al. HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy. J Immunol 2002;168:5900-6.
9. Khong HT, Restifo NP. Natural selection of tumor variants in the generation of 'tumor escape' phenotypes. Nat Immunol 2002;3:999-1005.
10. Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 1998;392:86-9.
11. Dhodapkar KM, Krasovsky J, Williamson B, Dhodapkar MV. Antitumor monoclonal antibodies enhance cross-presentation of cellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. J Exp Med 2002;195:125-33.
12. Heath WR, Carbone FR. Cross-presentation in viral immunity and self-tolerance. Nat Rev Immunol 2001;1:126-34.
13. Kurts C, Miller JF, Subramaniam RM et al. Major histocompatibility complex class I-restricted cross-presentation is biased towards high dose antigens and those released during cellular destruction. J Exp Med 1998;188:409-14.
14. Nouri-Shirazi M, Banchereau J, Bell D et al. Dendritic cells capture killed tumor cells and present their antigens to elicit tumor-specific immune responses. J Immunol 2000;165:3797-803.
15. Berard F, Blanco P, Davoust J et al. Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells. J Exp Med 2000;192: 1535-44.
16. Subklewe M, Paludan C, Tsang ML et al. Dendritic cells cross-present latency gene products from Epstein-Barr virus-transformed B cells and expand tumor-reactive CD8(+) killer T cells. J Exp Med 2001;193:405-11.
17. Chaperot L, Chokri M, Jacob MC et al. Differentiation of antigen-presenting cells (dendritic cells and macrophages) for therapeutic application in patients with lymphoma. Leukemia 2000;14:1667-77.
18. Stainer CJ, Miflin G, Anderson S et al. A comparison of two different systems for CD34+ selection of autologous or allogeneic PBSC collections. J Hematother 1998;7:375-83.
19. Urbano-Ispizua A, Solano C, Brunet S, et al. Allogeneic transplantation of purified CD34+ cells from peripheral blood: Spanish experience of 62 cases. [Spanish Group of allo-PBT.] Bone Marrow Transplant 1998;21 Suppl 3:S71-74.
20. + peripheral blood stem cells for autografting in patients with breast cancer. Br J Haematol 1997;97:881-8.
21. Plumas J, Jacob MC, Chaperot L et al. Tumor B cells from non-Hodgkin's lymphoma are resistant to CD95 (Fas/Apo-1)-mediated apoptosis. Blood 1998;91:2875-85.
22. Fadok VA, Bratton DL, Henson PM. Phagocyte receptors for apoptotic cells: recognition, uptake, and consequences. J Clin Invest 2001;108:957-62.
23. Shacter E, Williams JA, Hinson RM et al. Oxidative stress interferes with cancer chemotherapy: inhibition of lymphoma cell apoptosis and phagocytosis. Blood 2000;96:307-13.
24. Anderson HA, Englert R, Gursel I, Shacter E. Oxidative stress inhibits the phagocytosis of apoptotic cells that have externalized phosphatidylserine. Cell Death Differ 2002;9:616-25.
25. Manches O, Lui G, Chaperot L et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood 2003;101:949-54.
26. Selenko N, Maidic O, Draxier S et al. CD20 antibody (C2B8)-induced apoptosis of lymphoma cells promotes phagocytosis by dendritic cells and cross-priming of CD8+ cytotoxic T cells. Leukemia 2001;15:1619-26.
27. Voll RE, Herrmann M, Roth EA et al. Immunosuppressive effects of apoptotic cells. Nature 1997;390:350-1.
28. Fadok VA, Bratton DL, Konowal A et al. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J Clin Invest 1998;101: 890-8.